Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

Vermij, L; Jobsen, JJ; Leon-Castillo, A; Brinkhuis, M; Roothaan, S; Powell, ME; de Boer, SM; Khaw, P; Mileshkin, LR; Fyles, A; Leary, A; Genestie, C; Jurgenliemk-Schulz, IM; Crosbie, EJ; Mackay, HJ; Nijman, HW; Nout, RA; Smit, VTHBM; Creutzberg, CL; Horeweg, N; Bosse, T; TransPORTEC Consortium

Author(s): Vermij, L; Jobsen, JJ; Leon-Castillo, A; Brinkhuis, M; Roothaan, S; Powell, ME; de Boer, SM; Khaw, P; Mileshkin, LR; Fyles, A; Leary, A; Genestie, C; Jurgenliemk-Schulz, IM; Crosbie, EJ; Mackay, HJ; Nijman, HW; Nout, RA; Smit, VTHBM; Creutzberg, CL; Horeweg, N; Bosse, T; TransPORTEC Consortium;
Details: Publication Year 2023-03,Volume 128,Issue #7,Page 1360-1368
Journal Title: British Journal of Cancer
Publication Type: Research article
Abstract: BACKGROUND: Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement. METHODS: Paraffin-embedded tumour samples of women with high-risk EC (HR-EC) from the PORTEC-3 trial (n = 424), and a Dutch prospective clinical cohort called MST (n = 256), were used. All cases were molecularly classified. Expression of L1CAM, ER and PR were analysed by whole-slide immunohistochemistry and CTNNB1 mutations were assessed with a next-generation sequencing. Kaplan-Meier method, log-rank tests and Cox's proportional hazard models were used for survival analysis. RESULTS: In total, 648 HR-EC were included. No independent prognostic value of ER, PR, L1CAM, and CTNNB1 was found, while age, stage, and adjuvant chemotherapy had an independent impact on risk of recurrence. Subgroup-analysis showed that only in NSMP HR-EC, ER-positivity was independently associated with a reduced risk of recurrence (HR 0.33, 95%CI 0.15-0.75). CONCLUSIONS: We confirmed the prognostic impact of the molecular classification, age, stage, and adjuvant CTRT in a large cohort of high-risk EC. ER-positivity is a strong favourable prognostic factor in NSMP HR-EC and identifies a homogeneous subgroup of NSMP tumours. Assessment of ER status in high-risk NSMP EC is feasible in clinical practice and could improve risk stratification and treatment.
Publisher: Springer Nature
Keywords: Female; Humans; Prognosis; Receptors, Estrogen; Immunohistochemistry; *Neural Cell Adhesion Molecule L1/metabolism; Prospective Studies; *Endometrial Neoplasms/pathology; Biomarkers, Tumor/genetics/analysis
Department(s): Radiation Oncology; Medical Oncology
PubMed ID: 36690721
Publisher's Version: https://doi.org/10.1038/s41416-023-02141-0
Open Access at Publisher's Site: https://doi.org/10.1038/s41416-023-02141-0
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-07-11 06:23:40

Last Modified: 2023-07-11 06:25:37